First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A plus O) plus /- radiotherapy (RT): Results from the FLUORO study

被引：0
|
作者：
Chong, Geoffrey
Lee, Denise
Lee, Sze Ting
Grobler, Anneke
Khor, Richard
Campbell, Belinda A.
Thachil, Thanuja
Manos, Kate
Martynchyk, Arina
Douglas, Genevieve
Keane, Colm
Palmer, Jodie
Hawkes, Eliza Anne
机构：
[1] Grampians Hlth, Ballarat, Vic, Australia
[2] Eastern Hlth, Box Hill, Vic, Australia
[3] Austin Hlth, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Res Inst, Melbourne, Australia
[6] La Trobe Univ, Melbourne, Vic, Australia
[7] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[8] Austin Hlth, Austin, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Australia
[10] Grampians Hlth, Ballarat, Vic, Australia
[11] Flinders Med Ctr, Adelaide, SA, Australia
[12] Univ Queensland, Frazer Inst, Brisbane, Qld, Australia
[13] Olivia NewtonJohn Canc Wellness & Res Ctr, Heidelberg, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7070
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
    Johnson, M.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Trukhin, D.
    Kim, S.
    Ursol, G.
    Hussein, M.
    Lim, F.
    Yang, C.
    Araujo, L.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Peters, S.
    Garon, E.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S844 - S844
  • [32] Durvalumab ± tremelimumab plus chemotherapy as first-line treatment for mNSCLC: results from the Phase 3 POSEIDON study
    Kern, Jens
    Johnson, Melissa L.
    Cho, Byoung Chul
    Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Laktionov, Konstantin
    Vasiliev, Aleksandr
    Kim, Sang-We
    Ursol, Grygorii
    Hussein, Maen
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz Henrique
    Saito, Haruhiro
    Reinmuth, Niels
    Shi, Xiaojin
    Poole, Lynne
    Medic, Nenad
    Peters, Solange
    Garon, Edward B.
    Mok, Tony
    Thomas, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 146 - 146
  • [33] Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
    Rodriguez-Abreu, Delvys
    Johnson, Melissa Lynne
    Hussein, Maen A.
    Cobo, Manuel
    Patel, Anjan Jayantilal
    Secen, Nevena Milica
    Lee, Ki Hyeong
    Massuti, Bartomeu
    Hiret, Sandrine
    Yang, James Chih-Hsin
    Barlesi, Fabrice
    Lee, Dae Ho
    Paz-Ares, Luis G.
    Hsieh, Robert Wenchen
    Miller, Karen
    Patil, Namrata
    Twomey, Patrick
    Kapp, Amy, V
    Meng, Raymond
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Ferrajoli, Alessandra
    Yilmaz, Musa
    Thompson, Philip A.
    Konopleva, Marina
    Green, Michael R.
    Sampath, Deepa
    Neelapu, Sattva S.
    Takahashi, Koichi
    Masarova, Lucia
    Burger, Jan A.
    Kanagal-Shamanna, Rashmi
    Khoury, Joseph D.
    Garg, Naveen
    Su, Xiaoping
    Wang, Xuemei
    Patel, Hinalben
    Ayala, Ana
    Kantarjian, Hagop
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2021, 138
  • [35] IMpower133: Primary efficacy and safety plus CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
    Mansfield, Aaron S.
    Liu, Stephen V.
    Szczesna, Aleksandra
    Havel, Libor
    Kzrakowski, Maciej
    Hochmair, Maximilian J.
    Huemer, Florian
    Losonczy, Gyorgy
    Johnson, Melissa L.
    Nishio, Makoto
    Reck, Martin
    Mok, Tony S.
    Lam, Sivuonthanh
    Shames, David S.
    Liu, Juan
    Kabbinavar, Fairooz
    Sandler, Alan
    Horn, Leora
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
    Finn, R. S.
    Kudo, M.
    Merle, P.
    Meyer, T.
    Qin, S.
    Ikeda, M.
    Xu, R.
    Edeline, J.
    Ryoo, B-Y.
    Ren, Z.
    Cheng, A-L.
    Galle, P. R.
    Kaneko, S.
    Kumada, H.
    Wang, A.
    Mody, K.
    Dubrovsky, L.
    Siegel, A. B.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1401
  • [38] BACOP/FND FIRST-LINE TREATMENT OF FOLLICULAR LYMPHOMA. MULTICENTRIC STUDY OF GISL PRELIMINARY RESULTS
    Luisi, D.
    Luminari, S.
    Amatetti, C.
    Merli, F.
    Brugiatelli, M.
    Baldini, L.
    Polimeno, G.
    Grinaldi, L.
    Fregoni, V.
    Giglio, M.
    Stellitano, C.
    Federico, M.
    Lombardo, M.
    ANNALS OF ONCOLOGY, 2004, 15 : 80 - 81
  • [39] BACOP/FR first-line treatment of follicular lymphoma. Multicentric study of GISL: Preliminary results
    Luisi, D.
    Luminari, S.
    Amatetti, C.
    Merli, F.
    Brugiatelli, M.
    Baldini, L.
    Polimeno, G.
    Grinaldi, L.
    Fregoni, V.
    Giglio, M.
    Stellitano, C.
    Marcheselli, L.
    Federico, M.
    Lombardo, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 59 - 59
  • [40] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
12345